These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 35895622)

  • 1. Analysis of genetic variants of frequently mutated genes in human papillomavirus-negative primary head and neck squamous cell carcinoma, resection margins, local recurrences and corresponding circulating cell-free DNA.
    Flach S; Kumbrink J; Walz C; Hess J; Drexler G; Belka C; Canis M; Jung A; Baumeister P
    J Oral Pathol Med; 2022 Sep; 51(8):738-746. PubMed ID: 35895622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of gene methylation in surgical margin imprints with locoregional recurrence in head and neck squamous cell carcinoma.
    Hayashi M; Wu G; Roh JL; Chang X; Li X; Ahn J; Goldsmith M; Khan Z; Bishop J; Zhang Z; Zhou XC; Richmon J; Agrawal N; Koch WM
    Cancer; 2015 Jun; 121(12):1957-65. PubMed ID: 25773145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular diagnosis of surgical margins and local recurrence in head and neck cancer patients: a prospective study.
    van Houten VM; Leemans CR; Kummer JA; Dijkstra J; Kuik DJ; van den Brekel MW; Snow GB; Brakenhoff RH
    Clin Cancer Res; 2004 Jun; 10(11):3614-20. PubMed ID: 15173067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutated p53 as a molecular marker for the diagnosis of head and neck cancer.
    van Houten VM; Tabor MP; van den Brekel MW; Kummer JA; Denkers F; Dijkstra J; Leemans R; van der Waal I; Snow GB; Brakenhoff RH
    J Pathol; 2002 Dec; 198(4):476-86. PubMed ID: 12434417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
    Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
    Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)-a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma.
    Flach S; Howarth K; Hackinger S; Pipinikas C; Ellis P; McLay K; Marsico G; Forshew T; Walz C; Reichel CA; Gires O; Canis M; Baumeister P
    Br J Cancer; 2022 May; 126(8):1186-1195. PubMed ID: 35132238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitochondrial DNA mutation in normal margins and tumors of recurrent head and neck squamous cell carcinoma patients.
    Dasgupta S; Koch R; Westra WH; Califano JA; Ha PK; Sidransky D; Koch WM
    Cancer Prev Res (Phila); 2010 Sep; 3(9):1205-11. PubMed ID: 20660573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison between mutational profiles in tumour tissue DNA and circulating tumour DNA in head and neck squamous cell carcinoma - A systematic review.
    Huang X; Leo P; Jones L; Duijf PHG; Hartel G; Kenny L; Vasani S; Punyadeera C
    Mutat Res Rev Mutat Res; 2024; 793():108477. PubMed ID: 37977279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma.
    Lim SM; Cho SH; Hwang IG; Choi JW; Chang H; Ahn MJ; Park KU; Kim JW; Ko YH; Ahn HK; Cho BC; Nam BH; Chun SH; Hong JH; Kwon JH; Choi JG; Kang EJ; Yun T; Lee KW; Kim JH; Kim JS; Lee HW; Kim MK; Jung D; Kim JE; Keam B; Yun HJ; Kim S; Kim HR
    Cancer Res Treat; 2019 Jan; 51(1):300-312. PubMed ID: 29747488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
    Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
    Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck.
    Brennan JA; Mao L; Hruban RH; Boyle JO; Eby YJ; Koch WM; Goodman SN; Sidransky D
    N Engl J Med; 1995 Feb; 332(7):429-35. PubMed ID: 7619114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted next-generation sequencing identifies molecular subgroups in squamous cell carcinoma of the head and neck with distinct outcome after concurrent chemoradiation.
    Tinhofer I; Stenzinger A; Eder T; Konschak R; Niehr F; Endris V; Distel L; Hautmann MG; Mandic R; Stromberger C; Weichert W; Budach V
    Ann Oncol; 2016 Dec; 27(12):2262-2268. PubMed ID: 27681865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative methylation analyses of resection margins predict local recurrences and disease-specific deaths in patients with head and neck squamous cell carcinomas.
    Tan HK; Saulnier P; Auperin A; Lacroix L; Casiraghi O; Janot F; Fouret P; Temam S
    Br J Cancer; 2008 Jul; 99(2):357-63. PubMed ID: 18594522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour-agnostic plasma assay for circulating tumour DNA predicts outcome in recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with a PD-1 inhibitor.
    Honoré N; van der Elst A; Dietz A; van Marcke C; Helaers R; Mendola A; Dahou H; Marbaix E; Poncin R; Seront E; Schmitz S; Limaye N; Galot R; Machiels JP
    Eur J Cancer; 2023 Dec; 195():113372. PubMed ID: 37913682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The genomic architectures of tumour-adjacent tissues, plasma and saliva reveal evolutionary underpinnings of relapse in head and neck squamous cell carcinoma.
    Wu P; Xie C; Yang L; Liu Y; Zeng J; Li X; Fang X; Fan Y; Zhao S; Kuang N; Xuan T; Xia X; Yi X; Huang Y; Yu Z; Tang Y
    Br J Cancer; 2021 Sep; 125(6):854-864. PubMed ID: 34230611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma cell-free DNA methylome profiling in pre- and post-surgery oral cavity squamous cell carcinoma.
    Patel KB; Padhya TA; Huang J; Hernandez-Prera JC; Li T; Chung CH; Wang L; Wang X
    Mol Carcinog; 2023 Apr; 62(4):493-502. PubMed ID: 36636912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next-generation sequencing (NGS) profiling of matched tumor and circulating tumor DNA (ctDNA) in head and neck squamous cell carcinoma (HNSCC).
    Economopoulou P; Spathis A; Kotsantis I; Maratou E; Anastasiou M; Moutafi MK; Kirkasiadou M; Pantazopoulos A; Giannakakou M; Edelstein DL; Sloane H; Fredebohm J; Jones FS; Kyriazoglou A; Gavrielatou N; Foukas P; Panayiotides I; Psyrri A
    Oral Oncol; 2023 Apr; 139():106358. PubMed ID: 36871349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutated
    Kampel L; Feldstein S; Tsuriel S; Hannes V; Carmel Neiderman NN; Horowitz G; Warshavsky A; Leider-Trejo L; Hershkovitz D; Muhanna N
    Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck.
    Honoré N; van Marcke C; Galot R; Helaers R; Ambroise J; van Maanen A; Mendola A; Dahou H; Marbaix E; Van Eeckhout P; Longton E; Magremanne M; Schmitz S; Limaye N; Machiels JP
    Ann Oncol; 2023 Dec; 34(12):1175-1186. PubMed ID: 37879442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.